诚意药业(603811) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥164,753,277.21, representing an increase of 18.85% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥40,608,073.60, a significant increase of 73.92% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥34,759,251.12, up by 59.19% compared to the previous year[2]. - The basic earnings per share for Q3 2024 was ¥0.13, reflecting a 73.92% increase year-on-year[3]. - The net profit for Q3 2024 was CNY 117,009,151.82, an increase from CNY 113,504,894.78 in Q3 2023, representing a growth of approximately 4.4%[19]. - The company reported a total profit of CNY 130,289,881.42 for Q3 2024, up from CNY 119,057,357.15 in Q3 2023, which is an increase of around 9.3%[19]. - Total operating profit for Q3 2024 was CNY 130,203,765.91, compared to CNY 118,836,688.91 in Q3 2023, marking an increase of approximately 9.2%[19]. - The company's total operating revenue for the first three quarters of 2024 reached ¥520,542,330.59, an increase of 13.3% compared to ¥459,487,529.22 in the same period of 2023[17]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,817,399,257.78, a decrease of 3.98% from the end of the previous year[3]. - The total assets as of September 30, 2024, amounted to ¥1,816,100,090.47, a decrease from ¥1,923,170,215.73 at the end of 2023[25]. - The company's total liabilities decreased from ¥696,153,933.51 to ¥569,209,861.57, a reduction of approximately 18.3%[16]. - The total liabilities decreased to ¥492,195,552.57 from ¥667,688,526.00 in the previous year[25]. - The equity attributable to shareholders increased from ¥1,192,314,263.44 to ¥1,243,953,189.56, showing a growth of about 4.3%[16]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥104,984,267.34, down by 15.75% year-on-year[2]. - Cash flow from operating activities for the first nine months of 2024 was ¥118,315,224.57, a decrease from ¥127,744,659.73 in the same period of 2023, showing a decline of about 7%[30]. - The net cash flow from financing activities for the year-to-date was -1,437.72 million RMB, primarily due to a decrease in new bank loan approvals compared to the previous year[8]. - The net cash flow from financing activities was negative at -¥206,487,663.79, compared to a positive cash flow of ¥15,435,818.71 in the previous year[22]. - The net cash flow from investing activities was ¥16,000,950.61, a significant improvement from -¥45,109,147.48 in the previous year[22]. Expenses and Income - The company recorded a tax expense of CNY 13,280,729.60 in Q3 2024, significantly higher than CNY 5,552,462.37 in Q3 2023, reflecting an increase of approximately 139.0%[19]. - The company's investment income decreased to CNY 30,981,776.88 in Q3 2024 from CNY 49,871,213.39 in Q3 2023, a decline of approximately 38.0%[19]. - The company's financial expenses for Q3 2024 were ¥3,885,407.04, an increase from ¥3,473,927.62 in Q3 2023, reflecting a growth of about 12%[28]. - The company reported an increase in other income of 82.61 million RMB, mainly from government financial subsidies received during the reporting period[8]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,344, with the largest shareholder holding 23.58% of the shares[10].